Bohemian Cos. to cancel $2.5M in Omni Bio debt upon transfer of assets

FORT COLLINS — Officials for Omni Bio Pharmaceutical Inc., which announced last month that it was shutting down, disclosed in a new regulatory filing Thursday an agreement with sole secured creditor Bohemian Investments LLC, in which about $2.5 million of Omni Bio’s debt will be canceled.

As part of the deal, all of Fort Collins-based Omni Bio’s remaining transferrable assets will be assigned to Bohemian affiliate Advent Bio Holdings LLC. Those assets include “patents co-owned by the Company, cell lines in frozen storage and related data reports, and the Company’s shares of stock in BioMimetix Pharmaceutical Inc.,” the filing made with the Securities and Exchange Commission states.

Officials for Fort Collins-based Bohemian Cos. declined comment Thursday. Former Omni Bio chief executive Bruce Schneider could not be reached for comment.

SPONSORED CONTENT

The many benefits of simple, coordinated healthcare

Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.

Omni Bio, a spinoff of University of Colorado technology founded in 2009, had been developing a recombinant form of the naturally occurring human protein Alpha-1 Antitrypsin for the treatment of a variety of inflammatory and immune-modulated diseases. The company’s shares were traded publicly over the counter under the ticker symbol OMBP.

Bohemian had held a security interest in Omni Bio’s assets through a loan and warrant purchase agreement from 2014. Thursday’s regulatory filing notes that, once the CU board of regents consents to the transfer of Omni Bio patent licenses with the school to Advent Bio Holdings, the $2.5 million in outstanding principal and interest owed by Omni Bio to Bohemian will be canceled.

In addition, Omni Bio announced Thursday that Schneider, chief science officer Charles Dinarello and chief financial officer John Riccardi resigned from their positions, as did board members Michael Kamarck, Albert Kramer, Sandra Wrobel and Michael Wort. Riccardi was appointed to fill a seat on the board of directors to “wind up any remaining administrative matters,” the filing said.